Agilon Health’s second quarter was marked by significant beats on both revenue and profitability, but the results did not prevent a notable drop in the company’s share price. Management attributed the quarter’s strong financials to operational improvements, including earlier identification of high-risk conditions and expanded adoption of clinical pathways, especially in chronic heart failure management. CEO Tim O’Rourke emphasized that these changes are structural rather than short-term fixes, noting, “Our transformation efforts are gaining traction, our physician partnerships continue to strengthen, and our operating model is becoming increasingly resilient, scalable, and durable.” The company’s enhanced data pipeline and investments in AI also played a role in driving improved outcomes and reducing unnecessary medical costs.
Is now the time to buy AGL? Find out in our full research report (it’s free for active Edge members).
agilon health (AGL) Q2 CY2026 Highlights:
- Revenue: $1.49 billion vs analyst estimates of $1.45 billion (7.2% year-on-year growth, 2.8% beat)
- Adjusted EPS: $2.15 vs analyst estimates of $0.27 (significant beat)
- Adjusted EBITDA: $69.57 million vs analyst estimates of $19.95 million (4.7% margin, significant beat)
- The company lifted its revenue guidance for the full year to $5.82 billion at the midpoint from $5.74 billion, a 1.3% increase
- EBITDA guidance for the full year is $85 million at the midpoint, above analyst estimates of $22.61 million
- Operating Margin: 0.8%, up from -8.3% in the same quarter last year
- Customers: 549,000, up from 426,000 in the previous quarter
- Market Capitalization: $1.45 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From agilon health’s Q2 Earnings Call
- Jack Slevin (Jefferies) pressed for details on why third quarter EBITDA guidance was flat despite strong first-half results and asked about seasonality in cost trends. CFO Jeff Schwaneke explained that Part D exposure is now minimal and earnings seasonality will be similar to prior years, while emphasizing ongoing payer negotiations for next year.
- Jailendra Singh (Truist Securities) questioned how much of the improved medical margin should be considered a sustainable base for modeling future years. Schwaneke clarified that prior year development was the main non-recurring factor and guided analysts to use the adjusted margin net of these items.
- Max Young (Deutsche Bank) sought clarification on the sources of medical cost moderation across different service categories. Schwaneke responded that moderation is most visible in inpatient, surgical, and ER trends, though overall levels remain elevated versus history.
- Ryan Langston (TD Cowen) asked for updates on the performance of a new risk contract and the extent of data pipeline adoption. Schwaneke stated that the contract is tracking to expectations but requires more time for full assessment, and confirmed over 80% of payers are now integrated into the enhanced data pipeline.
- Matthew Shea (Needham) inquired about which clinical conditions drove the recent risk score uplift and whether similar gains are repeatable. Schwaneke explained the lift was primarily due to expanded pathway adoption and improved diagnosis, with contributions expected to moderate as programs mature.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the pace and breadth of clinical pathway deployments, particularly for dementia and COPD; (2) progress on converting care coordination contracts to full risk in existing markets; and (3) continued improvement in operational standardization and cost trend discipline across physician groups. Additionally, updates on payer negotiations and the impact of technology investments on clinical outcomes will be key signposts for execution.
agilon health currently trades at $87.12, down from $107.85 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
